MCM
LUCD icon

MAI Capital Management’s Lucid Diagnostics LUCD Stock Holding History

MAI Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150 Buy
+130
New +$165 ﹤0.01% 4683

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

MAI Capital Management's LUCD Position: Q1 2026 in Review

MAI Capital Management opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 130 shares worth $150. The stake represents ﹤0.01% of the portfolio and ranks #4683 among its holdings.

103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • MAI Capital Management held 130 shares of Lucid Diagnostics worth $150 as of Q1 2026.
  • Lucid Diagnostics was a new MAI Capital Management position in Q1 2026.
  • Lucid Diagnostics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4683 holding.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.